Based on these results, we believe that there is a need to examine the safety profiles of lorlatinib and alectinib in greater detail, i.e., to compare the safety of lorlatinib with that of alectinib in terms of representative safety outcomes, including the incidence of any adverse events (AAEs), serious adverse events (SAEs), increased AST or ALT levels, nausea, diarrhea, and pneumonitis that are relatively ubiquitous with the use of ALK inhibitors and/or often influence the treatment course and prognosis. Here, GPT is linked to pneumonitis.